3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Dermatologic
1
Conditions
Melanoma
4
Carcinoma, Basal Cell
4
Sarcoma, Kaposi
1
Carcinoma, Squamous Cell
1
Carcinoma, Merkel Cell
1
Carcinoma
1
Interventions
Specimen Handling
3
Magnetic Resonance Spectroscopy
3
pembrolizumab
2
Semaxinib
2
Nivolumab
2
Docetaxel
2
tin etiopurpurin
1
entinostat
1
daromun
1
cabozantinib
1
Tumor Necrosis Factor-alpha
1
Therapeutics
1
Thalidomide
1
SUB1 protein, human
1
Ritonavir
1
Quality of Life
1
Psychiatric Rehabilitation
1
Patient Reported Outcome Measures
1
Palliative Care
1
Nutritional Support
1
Nelfinavir
1
Molecular Diagnostic Techniques
1
Interleukin-12
1
Immunotherapy
1
Gemcitabine
1
Filgrastim
1
Drug Therapy
1
Celecoxib
1
Brentuximab Vedotin
1
Biopsy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Sarcoma, Kaposi
×
daromun
×
Dermatologic
×
Clear all
NCT05329792
2023-10-06
IntriNSiC
Philogen S.p.A.
Phase 2
Unknown
70 enrolled